BSF Enterprise PLC Results of Annual General Meeting (1936S)
12 Julho 2022 - 8:08AM
UK Regulatory
TIDMBSFA
RNS Number : 1936S
BSF Enterprise PLC
12 July 2022
12 July 2022
BSF Enterprise plc
("BSF" or the "Company")
Results of Annual General Meeting
BSF Enterprise plc (LSE: BSFA), is pleased to announce that at
the Company's Annual General Meeting held earlier today, all
resolutions proposed were duly passed by shareholders by way of a
poll, the results of which were as follows:
Poll Results
Resolution For Against Abstain Discretionary Total
----------- -------- -------- -------------- -----------
1 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
2 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
3 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
4 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
5 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
6 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
7 Shares 43,864,905 - - - 43,864,905
-------- ----------- -------- -------- -------------- -----------
% 100 - - - 100
-------- ----------- -------- -------- -------------- -----------
The total number of ordinary shares in issue on 12 July 2022 was
85,783,409 shares. Of the ordinary shares in issue, 7,798,491
shares have been issued as restricted shares under the Company's
Restricted Share Plan or under agreements containing equivalent
terms, are subject to voting restrictions and were restricted from
being voted at the meeting. 56.25% of voting capital entitled to
vote at the meeting was instructed in respect of the resolutions
put to the Annual General Meeting.
The full text of the resolutions can be found in the Notice of
Annual General Meeting dated 17 June 2022, which is available on
the Company's website at: https://bsfenterprise.com/documents/
In accordance with the FCA's Listing Rule 9.6.2, copies of all
the resolutions passed by the Company's shareholders, other than
ordinary business will be submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further enquiries, please visit www.bsfenterprise.com or
contact:
BSF Enterprise PLC Via SEC Newgate
below
Geoff Baker - Non-Executive Director
Graham Duncan - Chief Financial
Officer
Shard Capital (Broker)
Damon Heath
Erik Woolgar 020 7186 9952
SEC Newgate (Financial Communications)
Bob Huxford 020 3757 6882
Elisabeth Cowell BSF@secnewgate.co.uk
George Esmond
LEI: 2138007PJT69H8FYLC06
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next
generation of biotechnological solutions - using cell-based tissue
engineering to help generate cultured meat, lab-grown leather, as
well as human corneas, collagen growth and skin substitutes, as
part of a radical transformation to deliver sustainable solutions
across a variety of sectors.
It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help
restore vision to millions of people. Building on this success, it
aims to produce the UK's first high quality lab-grown meat from its
laboratory in Newcastle the next 12 months, transforming the
meat-production industry towards an ethical and sustainable
practice.
BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as
well as through M&A. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers,
wholesalers and distributors to help manufacture the products at
scale.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUURARUUUBAAR
(END) Dow Jones Newswires
July 12, 2022 07:08 ET (11:08 GMT)
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
